



A Partnership Including  
Professional Corporations  
3150 Porter Drive  
Palo Alto, CA 94304-1212  
650-813-5000  
Facsimile 650-813-5100  
www.mwe.com

Boston  
Chicago  
London  
Los Angeles  
Miami  
Munich  
New York  
Orange County  
Silicon Valley  
Washington, D.C.

03CO  
9

**MCDERMOTT, WILL & EMERY**

March 11, 2002

Assistant Commissioner for Patents  
U.S. Patent and Trademark Office  
Washington, D.C. 20231

RE: Information Disclosure Statement

Applicant: Nathan  
Serial No: 09/865,966  
Filed: May 25, 2001  
Our File: 57557-013

Dear Sir/Madam:

Applicant herewith submits the following documents:

1. Transmittal of Information Disclosure Statement;
2. Information Disclosure Citation (Form PTO 1449);
3. copy of References;
4. this Transmittal Letter; and
5. a Return Postcard.

The Commissioner is authorized to charge any applicable fees and credit any overpayment to Deposit Account No. 50-0385. A duplicate letter is enclosed for that purpose.

Very truly yours,

James E. Eakin  
Reg. No. 27,874

Enclosures

I certify that this document and fee is being deposited on  
March 12, 2002 with the U.S. Postal Service as first class  
mail under 37 C.F.R. 1.8 and is addressed to the Assistant  
Commissioner for Patents, Washington, D.C. 20231.

  
Signature of Person Mailing Correspondence

R. Kait McLendon Kent

Typed or Printed Name of Person Mailing Correspondence

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
**(Under 37 CFR 1.97(b) or 1.97(c))**

Docket No.  
**57557-013**

In Re Application Of: **Asher Nathan**


Serial No.  
**09/865,966**

Filing Date  
**05/05/2001**

Examiner  
**unassigned**

Group Art Unit  
**unassigned**

Title: **DRUG AMINO ACIDS CHIMERIC MOLECULES**



Address to:

**Assistant Commissioner for Patents  
Washington, D.C. 20231**

**37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application; within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or before the mailing date of a first Office Action on the merits, whichever event occurs last.

**37 CFR 1.97(c)**

2. ☐ The Information Disclosure Statement submitted herewith is being filed after three months of the filing of a national application, or the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or after the mailing date of a first Office Action on the merits, whichever occurred last but before the mailing date of either:

1. a Final Action under 37 CFR 1.113, or
  2. a Notice of Allowance under 37 CFR 1.311,
- whichever occurs first.

Also submitted herewith is:

- ☐ a certification as specified in 37 CFR 1.97(e);

**OR**

- ☐ the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under 37 CFR 1.97(c).

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
57557-013

In Re Application Of: Asher Nathan

Serial No.  
09/865,966

Filing Date  
05/05/2001

Examiner  
unassigned

Group Art Unit  
unassigned

THE DRUG AMINO ACIDS CHIMERIC MOLECULES

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 50-0385 as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of \_\_\_\_\_
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. \_\_\_\_\_)

\_\_\_\_\_) on \_\_\_\_\_  
(Date)

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I certify that this document and fee is being deposited on March 12, 2002 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

R. Kait McLendon Kent  
Signature of Person Mailing Correspondence

R. Kait McLendon Kent


\_\_\_\_\_  
Typed or Printed Name of Person Mailing Correspondence

\*This certificate may only be used if paying by deposit account.

James E. Eakin  
Signature

Dated: March 12, 2002

CC:



## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

57557-013

Application Number

09/865,966

Applicant(s)

Asher Nathan

Filing Date

05/05/2001

Group Art Unit

unassigned

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A	US 567,588A	10/22/1996	Gold et al			
	B	US 5,270,163A	12/14/1993	Gold et al			

## FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO
	AA	92/14843 A1	09/03/1992	WO				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AAA	POUL et al "Selection of tumor-specific internalizing human antibodies from phage libraries" August 2000, Vol 301, pages 1149-1161.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.